Performances of a novel chemiluninescence ABEI-based NT-proBNP immunoassay.

Authors :: UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service de pathologie cardiovasculaire
UCL - (SLuc) Service de biochimie médicale
Adamantidou, Christina
Ahn, Sylvie
Rousseau, Michel
Gruson, Damien
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service de pathologie cardiovasculaire
UCL - (SLuc) Service de biochimie médicale
Adamantidou, Christina
Ahn, Sylvie
Rousseau, Michel
Gruson, Damien
Source :: Acta cardiologica, Vol. 77, no.2, p. 176-179 (2022)
Publication Year :: 2022
Abstract: Natriuretic peptides are widely used in clinical practice as cardiac markers for early diagnosis, prognosis and for the monitoring of treatment efficiency of heart Failure (HF). According to the clinical relevance of natriuretic peptides testing, it is important to assess the performances of novel platform for testing. Our study showed the overall good performances of a new NT-proBNP ABEI-based automated immunoassay.

Tools